Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emicizumab

Roche Basel Switzerland

Roche wins FDA priority review for haemophilia A drug

Emicizumab prophylaxis could be approved early next year

- PMLiVE

Shire to customise MicroHealth’s app for haemphilia patients

Will collaborate with the digital health firm on its mobile monitoring tool

- PMLiVE

Biocon backs away from biosimilar filings in Europe

EMA asks biotech to withdraw Herceptin and Neulasta biosimilar filings

Shire Basingstoke

Shire files dry eye drug lifitegrast in Europe

Analysts predict Xiidra could become a $1bn product

- PMLiVE

Shire strikes bi-specific antibody deal with Novimmune

Pharma giant obtains licence for haemophilia A candidate

Roche Basel Switzerland

Roche out-licenses lebrikizumab rights to Dermira

Swiss drug maker stands to receive $80m upfront for the drug

- PMLiVE

Attracting doctors to low-demand specialties: A role for industry?

 One of the major problems that healthcare systems around the world face is a paucity of medically qualified staff entering particular specialties and subspecialties. This can be due to a...

Porterhouse Medical Group

Roche Basel Switzerland

Ocrevus off to a flying start as Roche raises 2017 forecasts

New multiple sclerosis drug posts positive results in first quarter

- PMLiVE

NICE backs Cancer Drugs Fund support for Roche’s Gazyvaro

Lymphoma treatment will be used in conjunction with chemotherapy

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Shire wins block of Roche’ ‘misinformation’ over emicizumab

Obtains a preliminary injunction from a German court

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links